

BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Technology Center 1600

Facsimile Transmission

To:	Name:	Mark Farley
	Company:	
	Fax Number:	212 391 0525
	Voice Phone:	212 278 0418
From:	Name:	Anne Holleran
	Official Fax Number:	(703) 872-9306
	Official After Final Fax Number:	(703) 872-9307
	Voice Phone:	703-308-8892

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

This is proposed examiner's amendment for 08/481,809. Please note that due to the proposed examiner's amendment of claim 138, claim 139 needs to be canceled because it will have the same scope as claim 138. Claim 145 needs to be canceled because it has the same scope as claim 148.

My telephone number is 571 272 0833. Anne Holleran

Date and time of transmission: Tuesday, February 03, 2004 11:39:04 AM
Number of pages including this cover sheet: 08

EXHIBIT C

Applicants: Livingston et al.
U.S. Serial No.: 08/475,784
Filed: June 7, 1995

Application/Control Number: 08/481,809
Art Unit: 1642

Page 2

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with xxx on xxx.

The application has been amended as follows:

In the specification:

at page 38, line 13, after "(Kensil et al. 1991)", the following was added:

Coursely chopped Q. saponaria bark [approximately 1 cm square, obtained from Hauser Chemicals, Boulder, CO] was stirred with 10 ml of water/g of bark at room temperature for 1 h. The extract was centrifuged and the supernatant containing the solubilized saponins was saved. The extraction step was repeated on the bark pellet and the two supernatants were pooled. To remove nonsaponin components, the supernatant pool was lyophilized, redissolved in 40 mM acetic acid in water at a concentration of 250 mg/ml (w:v) and either chromatographed through Sephadex G-50 (medium, Pharmacia, Piscataway, NJ) in 40 mM acetic acid with the hemolytic activity localized in the void volume fraction, or dialyzed against 40 mM acetic acid with the hemolytic activity retained by the dialysis membrane. The hemolytic fraction was lyophilized and redissolved at a concentration of 200 mg/ml in 40 mM acetic acid in

BEST AVAILABLE COPY

Page 3

Application/Control Number: 08/481,809

Art Unit: 1642

chloroform/methanol/water (62/32/6, v/v/v): 1 g of this fraction was applied to Silica Lichroprep (E.M. Science, Gibbston, NJ: 40 to 63 μ m particle size, 2.5 cm I.D. x 20 cm height) and eluted isocratically in the solvent used to solubilize the saponins. The elution of saponins was monitored by carbohydrate assay. Fractions containing the saponins of interest were identified by reverse phase TLC with visualization with Bial's reagent (Sigma, ST. Louis, M)) pooled individually, and rotavapped to dryness. The fractions from the silica chromatography were then redissolved in 40 mM acetic acid in 50% methanol and loaded on a semipreparative HPLC column (Vydac C₄, 5 μ m particle size, 3000 nm pore size, 10 mm I.D. X 25 cm length). Saponin peaks detected by absorbance at 214 nm were eluted by using a methanol gradient at a flow rate of 4 ml/min and individually rotavapped to dryness. Purity of saponins was assessed by analytic HPLC (Vydac C₄, 5 μ m particle size, 3000 nm pore size, 4.6 mm I.D. x 25 cm length) with a gradient of 0.1% TFA in acetonitrile. QS-21 is defined as the adjacent active reverse phase HPLC fraction 21 from Q. Saponaria bark extract.

In the claims:

Claims 139 and 145 were canceled.

Claim 138.

A composition which comprises:

a) a conjugate of (i) a ganglioside derivative [an oligosaccharide portion of a ganglioside comprising an altered ceramide moiety including an altered sphingosine base], wherein the ganglioside derivative is a ganglioside cleaved with ozone, and wherein an aldehyde group is introduced at the C4 position of the sphingosine portion

BEST AVAILABLE COPY

Page 4

Application/Control Number: 08/481,809
Art Unit: 1642

of the ganglioside, and (ii) Keyhole Limpet Hemocyanin[an immunogenic protein-based carrier;], wherein the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the sphingosine base and the nitrogen of the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21], a saponin derivable from the bark of a Quillaja saponaria Molina tree]; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated [oligosaccharide portion of the ganglioside derivative] is an amount between about 1 μ g and about 200 μ g, the amount of [the saponin] QS-21 is an amount between about 10 μ g and about 200 μ g, and [when the ganglioside is GM2 the GM2:Keyhole Limpet Hemocyanin] the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and [such saponin] QS-21 being effective to stimulate or enhance production in a subject of an antibody to the ganglioside,

[wherein in the conjugate the oligosaccharide portion of the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CII₂ group].

Claim 146.

The composition of 138 wherein the amount of the [saponin]

QS-21 is about 200 μ g.

BEST AVAILABLE COPY

Page 5

Application/Control Number: 08/481,809

Art Unit: 1642

Claim 148

The composition of claim 138 which comprises:

a) a conjugate of (i) ganglioside derivative [an oligosaccharide portion of a ganglioside comprising an altered ceramide moiety including an altered sphingosine base], wherein the ganglioside derivative is a ganglioside cleaved with ozone, and wherein an aldehyde group is introduced at the C4 position of the sphingosine portion of the ganglioside, and (ii) Keyhole Limpet Hemocyanin [an immunogenic protein-based carrier;], wherein the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the sphingosine base and the nitrogen of the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21 [, a saponin derivable from the bark of a Quillaja saponaria Molina tree]; and

c) a pharmaceutically acceptable carrier,

wherein the amount of the conjugated [oligosaccharide portion of the]ganglioside derivative is an amount between about 1 μg and about 200 μg , the amount of [the saponin] QS-21 is about 100 μg , and [when the ganglioside is GM2 the GM2:Keyhole Limpet Hemocyanin] the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and [such saponin] QS-21 being effective to stimulate or enhance production in a subject of an antibody to the ganglioside,

[wherein in the conjugate the oligosaccharide portion of the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside

BEST AVAILABLE COPY

Page 6

Application/Control Number: 08/481,809

Art Unit: 1642

derivative and to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH₂ group and].

Claim 150.

A method of stimulating or enhancing production of

antibodies to a ganglioside in a subject which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of (i) a ganglioside derivative [an oligosaccharide portion of a ganglioside comprising an altered ceramide moiety including an altered sphingosine base], wherein the ganglioside derivative is a ganglioside cleaved with ozone, and wherein an aldehyde group is introduced at the C4 position of the sphingosine portion of the ganglioside, and (ii) Keyhole Limpet Hemocyanin[an immunogenic protein-based carrier;], wherein the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the sphingosine base and the nitrogen of the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21[, a saponin derivable from the bark of a Quillaja saponaria Molina tree]; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated [oligosaccharide portion of the]ganglioside derivative is an amount between about 1 μ g and about 200 μ g, the amount of [the saponin] QS-21 is an amount between about 10 μ g and about 200 μ g, and [when the ganglioside is GM2 the GM2:Keyhole Limpet Hemocyanin] the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and

Application/Control Number: 08/481,809
Art Unit: 1642

[such saponin] QS-21 being effective to stimulate or enhance production in a subject of an antibody to the ganglioside,

[wherein in the conjugate the oligosaccharide portion of the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH_2 group, and] so as to thereby stimulate or enhance production in the subject of the antibody to the ganglioside.

Claim 151.

A method of treating a human subject having cancer which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of (i) a ganglioside derivative [an oligosaccharide portion of a ganglioside comprising an altered ceramide moiety including an altered sphingosine base], wherein the ganglioside derivative is a ganglioside cleaved with ozone, and wherein an aldehyde group is introduced at the C4 position of the sphingosine portion of the ganglioside, and (ii) Keyhole Limpet Hemocyanin [an immunogenic protein-based carrier], wherein the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the sphingosine base and the nitrogen of the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21 [, a saponin derivable from the bark of a Quillaja saponaria Molina tree]; and

c) a pharmaceutically acceptable carrier;

BEST AVAILABLE COPY

Application/Control Number: 08/481,809

Page 8

Art Unit: 1642

wherein the amount of the conjugated [oligosaccharide portion of the]ganglioside derivative is an amount between about 1 μ g and about 200 μ g, the amount of [the saponin] QS-21 is an amount between about 10 μ g and about 200 μ g, and [when the ganglioside is GM2 the GM2:Keyhole Limpet Hemocyanin] the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the relative amounts of such conjugate and [such saponin] QS-21 being effective to stimulate or enhance production in a subject of an antibody to the ganglioside,

[wherein in the conjugate the oligosaccharide portion of the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and to an ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH₂ group, and] so as to thereby stimulate or enhance production in the subject of the antibody to the ganglioside.

Claim 161. The method of claim 160, wherein the conjugate and the [saponin] QS-21 are mixed on the day of administration to the subject.